PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-272.88%
Negative EBIT growth while AVXL is at 2.19%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-59.22%
Negative operating income growth while AVXL is at 2.19%. Joel Greenblatt would press for urgent turnaround measures.
-272.88%
Negative net income growth while AVXL stands at 0.96%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-252.38%
Negative EPS growth while AVXL is at 9.09%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-313.33%
Negative diluted EPS growth while AVXL is at 9.09%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
10.47%
Share count expansion well above AVXL's 3.64%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
-20.54%
Reduced diluted shares while AVXL is at 3.64%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
-64.88%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-57.97%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-16444.97%
Negative 10Y OCF/share CAGR while AVXL stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-31629.64%
Negative 5Y OCF/share CAGR while AVXL is at 58.30%. Joel Greenblatt would question the firm’s operational model or cost structure.
-47124.26%
Negative 3Y OCF/share CAGR while AVXL stands at 48.71%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-24144.03%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-61703.68%
Negative 5Y net income/share CAGR while AVXL is 61.35%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-67595.61%
Negative 3Y CAGR while AVXL is 58.82%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
No Data
No Data available this quarter, please select a different quarter.
1169.73%
5Y equity/share CAGR above 1.5x AVXL's 240.54%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
1236.68%
3Y equity/share CAGR above 1.5x AVXL's 590.34%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-18.44%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-50.41%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-100.00%
We’re deleveraging while AVXL stands at 3.69%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
88.49%
R&D growth drastically higher vs. AVXL's 124.30%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
34.89%
We expand SG&A while AVXL cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.